What is CorDynamics?
CorDynamics operates as a premier preclinical CRO, dedicating its expertise to the intricate field of cardiovascular drug discovery and safety assessment. The company provides a comprehensive suite of services, leveraging advanced research models and cutting-edge techniques to address critical therapeutic areas. Their mission is to generate scientifically rigorous data that not only enhances the development of cardiovascular therapeutics but also streamlines the often-complex clinical development pathway. Serving a global clientele within the pharmaceutical and biotechnology industries, CorDynamics emphasizes a client-focused approach, ensuring timely and reliable results to accelerate innovation.
How much funding has CorDynamics raised?
CorDynamics has raised a total of $462K across 2 funding rounds:
Debt
$150K
Debt
$312K
Debt (2020): $150K with participation from PPP
Debt (2021): $312K led by PPP
Key Investors in CorDynamics
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for CorDynamics?
With a substantial late-stage funding context, CorDynamics is strategically positioned for significant expansion and further enhancement of its service offerings. The recent strategic investment likely signals a phase of scaling operations, potentially investing in new research technologies, expanding laboratory capacity, or forging deeper partnerships within the pharmaceutical and biotech ecosystem. This capital infusion is expected to bolster their ability to provide high-quality, data-driven insights, further solidifying their role as a key player in accelerating the development of novel cardiovascular treatments and improving patient outcomes globally.
See full CorDynamics company page
